United Therapeutics (UTHR) Rule 144 Notice — 11,000 Shares via Morgan Stanley
Rhea-AI Filing Summary
Form 144 notice for proposed sale of securities under Rule 144. The filing shows 11,000 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on 08/21/2025 with an aggregate market value of $3,396,248.90 and the issuer reported 45,226,262 shares outstanding. The securities were acquired on 08/21/2025 by stock option exercise and payment was in cash. The filing also lists multiple recent sales by Paul Mahon totaling 66,000 shares in the past three months. The notice includes the standard signature representation that the seller has no undisclosed material adverse information.
Positive
- Detailed transaction disclosure: The filing lists the exact shares, broker, sale date, and acquisition method, supporting regulatory transparency.
- Broker identified: Sales are to be executed through Morgan Stanley Smith Barney LLC, providing a clear execution venue.
- Seller certification included: The signer represents no undisclosed material adverse information, consistent with Rule 144 requirements.
Negative
- Frequent insider sales: Seven transactions in the past three months total 66,000 shares, increasing available share supply.
- Missing issuer identification: The provided extract does not state the issuer name in the issuer information section.
- Partial filer contact data: Submission contact fields in the extract are blank, limiting traceability of the filing origin.
Insights
TL;DR: Insider executed options and repeatedly sold shares; total recent disposals equal 66,000 shares, indicating notable insider liquidity.
The filing documents a Rule 144 notice for 11,000 common shares to be sold via Morgan Stanley on 08/21/2025, acquired the same day via option exercise and paid in cash. The inclusion of seven prior sales by the same person over six weeks is material for share supply; those transactions total 66,000 shares. The filing is procedural and provides transparent transaction detail but does not disclose the issuer name in the provided tables.
TL;DR: The filing meets Rule 144 disclosure requirements but omits issuer identification in the provided extract.
The notice contains the required sale and acquisition details, broker identification, and the seller's certification regarding undisclosed material information, supporting compliance with securities rules. However, the provided content lacks a clearly stated issuer name and some filer contact fields are blank, which reduces clarity for stakeholders reviewing governance and insider activity records.